Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
- PROTECT Investigators
- University of Groningen
- University of New South Wales
- Columbia University
- University of Washington
- University of Leicester General Hospital
- Travere Therapeutics
- JAMCO Pharma Consulting AB
- University of São Paulo
- University of Minnesota Medical School
- Ohio State University Wexner Medical Center
- University of Michigan Medical School
- British Hospital of Buenos Aires
- Concord Repatriation General Hospital
- Sydney University Biological Informatics and Technology Centre (SUBIT)
Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
202
Citations
(Scopus)